ReviewInternational journal of surgery (London, England)2026
The landscape of gut microbiota in hepatocarcinogenesis: a comprehensive review of pathogenesis and therapeutic interventions.
Review in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gut microbiota composition in responders vs. non-responders with hepatocellular carcinoma under ICI therapy: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Perioperative gut microbial ecology: a new frontier for improving the prognosis of hepatocellular carcinoma surgery.Precision clinical medicine · 2026Review
- The Ganoderma atrum Polysaccharide PSG-1 Attenuates Acrylamide-Induced Hepatotoxicity by Modulating the FXR-FGF15-Mediated Gut-Liver Axis.Molecular nutrition & food research · 2026Article
- Bacterial Extracellular Vesicles in the Pathogenesis and Treatment of Liver Diseases.Journal of gastroenterology and hepatology · 2026Review
- Polysaccharides-gut microbiota interaction: mechanisms regulating the hepatocellular carcinoma immune microenvironment.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary liver cancer (PLC) represents a significant global health burden, with hepatocellular carcinoma (HCC) being its predominant subtype. The gut microbiota plays a crucial role in the pathogenesis, treatment, and postoperative recovery of HCC through its regulatory functions along the gut-liver axis. This review systematically elucidates the role of gut microbiota dysbiosis and associated metabolites in the pathogenesis of HCC, specifically addressing the underlying mechanisms whereby gut microbiota and their metabolites mediate hepatic metabolic reprogramming, remodel the immune microenvironment, and promote HCC progression through crosstalk with intratumoral bacteria. It further explores the impact of the gut microbiota on immunotherapy, molecular targeted therapy, conventional chemotherapy, and surgical outcomes. Additionally, the review comprehensively outlines therapeutic strategies targeting the gut microbiota, including oral probiotics, antibiotics, fecal microbiota transplantation (FMT), particular small molecules, and traditional Chinese medicine. In summary, this review provides a comprehensive overview of how the gut microbiota influences the development and treatment of HCC and offers a theoretical foundation for targeting the microbiota to improve surgical prognosis in HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.